Thomas Niel

Thomas Niel

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Tread Carefully Before Buying Falling Knife Ford Stock

In other words, watch out with falling knife F stock. Shares may have rebounded from under $4 per share to over $5 per share in a matter of days. But it may pay to wait-and-see, and enter at a more compelling entry point.

Look For Better Buys Than Coronavirus Play INO Stock

Biotech investing is tough. If you have a background in this space, sure, knock yourself out. But if you are an investor looking for solid opportunities, look elsewhere, and avoid INO stock. As the overall market recovers, there are plenty of other screaming buys to consider.

Despite Stimulus, Uncertainty Remains for Grounded American Airlines Stock

Until we know how much the coronavirus from China will set the moribund airline back, stay on the sidelines with AAL stock.

Uncertainty Remains, but AVGO Stock Is a Buy at These Levels

What's the call? Buy AVGO stock, at today's reasonable prices. Even if shares fall short of retracing their high water mark, investors could see material near-term upside.

Even If Markets Rebound, XOM Stock Could Tread Water

Bottom line? I don't see XOM stock falling further. But I also don't see it retracing its high water mark. Considering other blue-chip names that could quickly rebound, stay on the sidelines with this stock, and pursue more solid opportunities.